Rexlemestrocel-L

allogeneic mesenchymal precursor cells · Mesoblast, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Rexlemestrocel-L, covering 2022-01-18 to 2026-03-23. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure [Phase 3]

See pricing